Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs GroupZolmax • 24 days ago
The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a...
Share to Feed
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( Olema or Olema Oncology , Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) has earned an average recommendation of Buy from the seven brokerages that are currently covering the stock...
EP Wealth Advisors LLC increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Free Report) by 831.1% in the third quarter, according to its most recent Form 13F filing...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report)s share price shot up 11.9% during mid-day trading on Wednesday . The company traded as high as $13.59 and last traded at...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 29th, there was short interest...
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...
This indicator may be signaling that OLMA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) fell 7% during trading on Tuesday following insider selling activity. The stock traded as low as $13.52 and last traded at...